Fineline Cube

Follow:
14778 Articles
Fresenius Kabi Ori Biotech CGT manufacturing IRO platform
CompanyDeals

Fresenius Kabi Partners with Ori Biotech to Integrate IRO Platform with Cell Processing Systems

Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024
CompanyDrug

Arvinas and Pfizer Present Positive TACTIVE-U Sub-Study Data at SABCS 2024

GSK Enters Multi-Program Partnerships with Relation Therapeutics for Fibrotic Diseases and Osteoarthritis
CompanyDeals

GSK Enters Multi-Program Partnerships with Relation Therapeutics for Fibrotic Diseases and Osteoarthritis

Novartis' Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024
CompanyDrug

Novartis’ Kisqali Shows Sustained Efficacy in NATALEE Study at SABCS 2024

Legend Biotech's Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial
CompanyDrug

Legend Biotech’s Carvykti Demonstrates High MRD Negativity Rates in Phase III CARTITUDE-4 Trial

Huadong Medicine's Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment
CompanyDrug

Huadong Medicine’s Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment

IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study
CompanyDrug

IMEIK Technology Receives NMPA Approval for Recombinant Human Hyaluronidase Clinical Study

Patronus Biotech's RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study
CompanyDrug

Patronus Biotech’s RSV Vaccine LYB005 Receives NMPA Approval for Clinical Study

Shanghai Pharmaceuticals' SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment
CompanyDrug

Shanghai Pharmaceuticals’ SRD4610 Receives FDA Orphan Drug Designation for ALS Treatment

Sperogenix Therapeutics' Agamree Receives NMPA Approval for Duchenne Muscular Dystrophy Treatment
CompanyDrug

Sperogenix Therapeutics’ Agamree Receives NMPA Approval for Duchenne Muscular Dystrophy Treatment

Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy
Policy / Regulatory

Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials
CompanyDrug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-4394 and HRS-3802 Clinical Trials